Evidence map›Paper›PMID 30496313›Full record

ArticlePloS one2018

A robust method for the estimation and visualization of IgE cross-reactivity likelihood between allergens belonging to the same protein family.

Maksymilian Chruszcz, A Brenda Kapingidza, Coleman Dolamore, Krzysztof Kowal

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Article
  3. A Human Monoclonal Antibody Displays Promiscuous Binding to Multiple Type 1 nsLTP Allergens.Journal of investigational allergology & clinical immunology · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Role of Small Molecule Ligands in IgE-Mediated Allergy.Current allergy and asthma reports · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Transcriptome Analysis ofFrontiers in microbiology · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Maksymilian ChruszczDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina, United States of America.ORCID 0000-0001-7521-5485
A Brenda KapingidzaDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina, United States of America.ORCID 0000-0001-8517-6299
Coleman DolamoreDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, South Carolina, United States of America.ORCID 0000-0002-7274-1014
Krzysztof KowalDepartment of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
University of South Carolina · USMedical University of Białystok · PL

Funding

Antigenic determinants of asthma-associated allergens for design of immunotherapy.R01AI077653 · NIAID · INDOOR BIOTECHNOLOGIES · PI MARTIN D. CHAPMAN, Maksymilian Chruszcz · 2009 to 2026
$9.5M
NIAID NIH HHS R01 AI077653
6 · The paper itself

Abstract

Among the vast number of identified protein families, allergens emanate from relatively few families which translates to only a small fraction of identified protein families. In allergy diagnostics and immunotherapy, interactions between immunoglobulin E and allergens are crucial because the formation of an allergen-antibody complex is necessary for triggering an allergic reaction. In allergic diseases, there is a phenomenon known as cross-reactivity. Cross-reactivity describes a situation where an individual has produced antibodies against a particular allergenic protein, but said antibodies fail to discriminate between the original sensitizer and other similar proteins that usually belong to the same family. To expound the concept of cross-reactivity, this study examines ten protein families that include allergens selected specifically for the analysis of cross-reactivity. The selected allergen families had at least 13 representative proteins, overall folds that differ significantly between families, and include relevant allergens with various potencies. The selected allergens were analyzed using information on sequence similarities and identities between members of the families as well as reports on clinically relevant cross-reactivities. Based on our analysis, we propose to introduce a new A-RISC index (Allergens'-Relative Identity, Similarity and Cross-reactivity) which describes homology between two allergens belonging to the same protein family and is used to predict the likelihood of cross-reactivity between them. Information on sequence similarities and identities, as well as on the values of the proposed A-RISC index is used to introduce four categories describing a risk of a cross-reactive reaction, namely: high, medium-high, medium-low and low. The proposed approach can facilitate analysis in component-resolved allergy diagnostics, generation of avoidance guidelines for allergic individuals, and help with the design of immunotherapy.

Indexed as

AllergensAmino Acid SequenceCross ReactionsHumansHypersensitivityImmunoglobulin ELikelihood FunctionsModels, MolecularProtein ConformationSequence AlignmentAllergensImmunoglobulin E

Identifiers

PMID30496313
PMCPMC6264518
OpenAlexW2902360204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.